Published in BJU Int on March 25, 2010
Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst (2012) 1.42
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Prostate cancer in young men: an important clinical entity. Nat Rev Urol (2014) 1.15
Geriatric considerations in the treatment of advanced prostate cancer. F1000Prime Rep (2014) 0.95
The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer. Oncologist (2012) 0.84
Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study. Br J Cancer (2013) 0.83
Optimizing the management of prostate cancer in senior adults: call to action. Oncologist (2012) 0.81
Management of advanced prostate cancer in senior adults: the new landscape. Oncologist (2012) 0.81
Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer. BMC Cancer (2015) 0.81
Australian patterns of prostate cancer care: Are they evolving? Prostate Int (2015) 0.81
Construction of a comorbidity index for prostate cancer patients linking state cancer registry with inpatient and outpatient data. J Registry Manag (2013) 0.81
Challenging treatment decision-making in older urologic cancer patients. World J Urol (2013) 0.81
Long term results of HDR brachytherapy in men older than 75 with localized carcinoma of the prostate. Rep Pract Oncol Radiother (2012) 0.80
Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer (2016) 0.79
Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. J Cancer Res Clin Oncol (2016) 0.78
Evaluation and Management of the Geriatric Urologic Oncology Patient. Curr Geriatr Rep (2015) 0.78
Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. BMC Cancer (2016) 0.78
Integrating Geriatric Assessment into Decision-Making after Prostatectomy: Adjuvant Radiotherapy, Salvage Radiotherapy, or None? Front Oncol (2015) 0.77
Four Distinct Health Profiles in Older Patients With Cancer: Latent Class Analysis of the Prospective ELCAPA Cohort. J Gerontol A Biol Sci Med Sci (2016) 0.77
A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical setting. Oncologist (2012) 0.77
Challenges of managing elderly men with prostate cancer. Nat Rev Clin Oncol (2014) 0.77
Use of treatment information from a state central cancer registry in prostate cancer research. J Registry Manag (2013) 0.76
Radical radiotherapy for high-risk prostate cancer in older men. Oncologist (2012) 0.75
Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population. Cancer (2016) 0.75
Prostate cancer: Individualized treatment recommended in older men. Nat Rev Urol (2010) 0.75
Re: management of prostate cancer in older men: recommendations of a working group of the international society of geriatric oncology. J Urol (2011) 0.75
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. Clin Interv Aging (2016) 0.75
[Prostate cancer. Current and practice-relevant news from urology in 2011]. Urologe A (2011) 0.75
[Therapy of castration-resistant prostate cancer]. Wien Klin Wochenschr (2012) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist (1969) 45.63
STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. JAMA (1963) 38.91
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol (2007) 11.04
Cancer screening in elderly patients: a framework for individualized decision making. JAMA (2001) 9.79
Cumulative illness rating scale. J Am Geriatr Soc (1968) 9.38
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
EAU guidelines on prostate cancer. Eur Urol (2007) 6.30
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol (2006) 4.36
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA (2008) 3.55
A brief clinical instrument to classify frailty in elderly people. Lancet (1999) 3.27
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol (2008) 3.06
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol (2005) 2.98
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol (2007) 2.90
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Management of cancer in the older person: a practical approach. Oncologist (2000) 2.50
Measuring comorbidity in older cancer patients. Eur J Cancer (2000) 2.04
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol (2009) 1.85
Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol (2003) 1.70
Predicting life expectancy in men with clinically localized prostate cancer. J Urol (2006) 1.42
Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol (2005) 1.37
Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int (2008) 1.35
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.14
Treatments for prostate cancer in older men: 1984-1997. Urology (2001) 1.04
Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis (2006) 0.99
Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol (2008) 0.95
Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int (2008) 0.88
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
EAU guidelines on prostate cancer. Eur Urol (2007) 6.30
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol (2012) 6.09
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med (2014) 4.76
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol (2004) 3.72
Against diagnosis. Ann Intern Med (2008) 3.69
Systematic review of complications of prostate biopsy. Eur Urol (2013) 3.66
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol (2002) 3.53
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol (2012) 3.30
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol (2012) 3.01
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol (2005) 2.98
Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol (2002) 2.98
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg (2004) 2.84
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol (2010) 2.82
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology (2008) 2.75
Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol (2014) 2.72
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72